Alkem Laboratories | Business Upturn

Latest Articles

Alkem Laboratories launches pertuza biosimilar for treatment of HER2-positive breast cancer

Corporates · Sep 22, 2025

blank

Alkem Labs shares jump 4% as Nomura maintains ‘Buy’ rating with Rs 5,430 target after strong Q1 results

Stock Market · Aug 13, 2025

blank

Alkem Laboratories shares jump 6% on strong Q1 results

Stock Market · Aug 12, 2025

blank

Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY

Quarterly Results · Aug 12, 2025

blank

Alkem Laboratories receives positive outcome from US FDA inspection at Taloja Bioequivalence Center

Corporates · Mar 13, 2025

By Aditya Bhagchandani

blank

Alkem Laboratories launches affordable generic empagliflozin in India

Corporates · Mar 12, 2025

blank

Alkem Laboratories shares drop 3% as revenue growth remains flat at Rs 3374 crore in Q3

Stock Market · Feb 7, 2025

blank

Alkem Laboratories Q3 FY25 Results: Revenue flat at Rs 3374 crore, Profit up 6% YoY

Corporates · Feb 7, 2025

By Aditya Bhagchandani

blank

Alkem Laboratories launches Kojiglo serum for facial hyperpigmentation in India

Corporates · Feb 4, 2025

blank

Alkem Laboratories sells Pithampur manufacturing facility to Rubicon Research for Rs 149 crore

Corporates · Jan 7, 2025

blank

Alkem Laboratories to transfer trade generics business to Alkem Wellness for Rs 750 crore

Corporates · Dec 10, 2024

blank

Alkem Laboratories Q2 FY25 Results: Revenue up 0.7% YoY to ₹3,414.67, Net Profit up 14.2% YoY

Corporates · Nov 13, 2024

By Aditya Bhagchandani

blank

Alkem Laboratories denies claims of its Pan-D and Clavam 625 products being not of standard quality

Corporates · Sep 27, 2024

blank

Alkem Laboratories sees ₹487 crore block deal as promoter likely offloads stake

Stock Market · Aug 22, 2024

By Aditya Bhagchandani

blank

Alkem Laboratories Block Deal: Shares worth Rs 118 crore change hands

Stock Market · Jun 25, 2024

By Aditya Bhagchandani

Showing 15 of 18 articles